Elanco Animal Health reported revenue of $1,265 million for the third quarter of 2026, an increase from $1,137 million in the prior year. The company achieved a net income of $18 million for the quarter, recovering from a net loss of $34 million in Q3 2025, driven by higher gross profits and lower restructuring charges.
Elanco Animal Health reported Q3 2026 revenue of $1.265 billion, an 11% increase year-over-year, driven by strong demand for its 'Big 6' innovation products. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS while achieving a net leverage ratio milestone of 2.9x.
Term
Q3 2026
“Third quarter results demonstrate Elanco is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accelerating cash flow.”
Jeff Simmons, President and CEO of Elanco
“Organic constant currency revenue growth of 9% was led by International Pet Health up 17% and U.S. Pet Health up 13%, as we saw strong veterinarian and pet owner demand for what we believe is 'best medicine' innovation for our 'Big 6' growth led by Zenrelia and Credelio Quattro.”
Elanco Animal Health Insider Timothy J. Bettington Sells $100K of Stock
Timothy J. Bettington sold 4,350 shares of Elanco Animal Health Inc at $23.00 a share, worth $100K in total on Oct 15, 2026. Shares held after the trade: 138,911 (-3.0%).